Xenetic Biosciences Reports Q2 2025 Financial Results

Xenetic Biosciences, Inc., a biopharmaceutical company, announced its financial performance for the second quarter of 2025. The company ended the period with $4.8 million in cash, showing a net loss of $0.7 million. Research and development expenses fell by 29.7% to $0.7 million, whereas general and administrative costs reduced by 41.8%, amounting to $0.7 million.

Significant milestones include an expanded partnership with The Scripps Research Institute to further develop DNase I in combination with CAR T-cell therapies. Collaborations with PeriNess Ltd. were also highlighted, focusing on clinical studies for treating various cancers.

Xenetic is advancing DNase-based technology for pancreatic cancer and other solid tumors, preparing for Phase 1 clinical trials. The company remains committed to building momentum across its development programs.